Abstract: A novel highly effective prokaryotic expression system is exemplified specifically by being used to produce the useful enzyme .beta.-glucuronidase (BG). This system uses a hybrid plasmid comprising BG gene promotor DNA. The level of expression of BG by an E. coli K-12 derivative host is in the 50% of total cellular protein range. The invention expression system also can be used to express other useful proteins, as disclosed herein.
Abstract: A method for inserting a selected restriction site into a double stranded genetic sequence at a selected tab site, and a linker for use therewith are disclosed. The method involves treating the genetic sequence with an opening agent (such as a restriction enzyme) so as to open both strands of the tab site. One then exposes the opened genetic sequence to two hexameric single stranded oligonucleotide linkers in the presence of a ligating enzyme. The two linkers have the same nitrogenous base sequence, a sequence which is partially palindromic complementary to itself at least one end of the nitrogenous sequence, but is not completely palindromic complementary to itself. Through use of this method, the two linkers are inserted in the opening with partial complementary overlap, and at least one of the linkers is affixed to each strand. Subsequently, the site is reclosed at the point of the insertion so as to contain a six base insertion.
Abstract: In a continuous interesterification process a fatty acid ester reactant, preferably a glyceride and optionally including free fatty acid, is contacted with an enzyme as interesterification catalyst which is preferably 1,3-selective and precipitated on an inert particulate support. The catalyst is packed in a fixed bed with contact times less than 2 hours which are sufficient to effect interesterification. The process is useful for producing POSt- and StOSt-rich fats suitable for use as cocoabutter substitute fats.
Abstract: A strain of Colletotrichum coccodes has been discovered which is selectively pathogenic toward eastern black nightshade (Solanum ptycanthum). Formulations comprising propagules of the fungal pathogen are useful for biological control of the eastern black nightshade weed, particularly in agricultural fields.
Type:
Grant
Filed:
May 29, 1985
Date of Patent:
December 29, 1987
Assignee:
The United States of America as represented by the Secretary of Agriculture
Abstract: The present invention discloses a rapid method of sequencing a relatively large segment of deoxyribonucleic acid. The method in part comprises high frequency insertion of a suitable transposon into a segment of DNA of interest. Preferable use of Mu transposons is described. A plasmid having mini-Mu transposons has been prepared and disclosed.
Type:
Grant
Filed:
December 13, 1984
Date of Patent:
December 29, 1987
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: A nonhygroscopic pulverulent composition for preparing beverages with a lasting effervescence comprises a first component or group of components mixed with a second component or group of components capable of reacting mutually in the presence of water to evolve a gas. Each of said components or group of components is impregnated with the dry residue of a saccharose liquor or of a saccharose derivative liquor containing a water-soluble or a mixture of water-soluble polymers.
Abstract: Improved expression vectors for amplifying expression of DNA sequence encoding a desired polypeptide beyond that expected by the vector copy number. The vector contains a DNA sequence within the replicon of the vector encoding RNA I and the primer RNA for initiation of DNA replication and their regulatory regions, said DNA sequence having an AT to GC mutuation at position 3029 in the two strands of pBR322; a promoter of RNA I or primer RNA and a restriction site for insertion of a DNA sequence encoding a desired polypeptide into the vector and operatively linking the DNA sequence to the expression control sequence. The AT to GC mutation causes an increase in the vector copy number and further amplifies the expression of the desired polypeptide operatively linked to the RNA I or primer RNA promoter beyond that expected by the copy number increase.
Abstract: Monoclonal antibodies that recognize a stage-specific antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as theraputic methods employing the cell suspensions.
Abstract: A selective method of suppressing the growth of cells which express a viral antigen on the surface thereof, which comprises administering to the cells a growth suppressing amount of a monoclonal antibody against said viral antigen, especially a method of suppressing the growth of hepatocytes or hepatoma cells persistently infected with HBsAg which comprises administering to the cells a growth suppressing or lethal amount of a complement fixing monoclonal IgM or IgG.sub.2a antibody against HBsAg.
Type:
Grant
Filed:
September 30, 1982
Date of Patent:
December 22, 1987
Assignees:
The Albert Einstein College of Medicine of Yeshiva University, The General Hospital Corporation
Inventors:
Daniel Shouval, David A. Shafritz, Jack R. Wands
Abstract: Antibiotic A41030, a complex of 7 individual factors, is produced by submerged, aerobic fermentation of new Streptomyces virginiae NRRL 12525, and Streptomyces virginiae NRRL 15156. The antibiotic factors are separated and possess antibacterial activity against Staphylococcus and Streptococcus species which are penicillin resistant. In addition, the antibiotic factors have shown inhibition of Streptococcus pneumonia Park I. The complex and the individual factors enhance feed efficiency in ruminant animals, and are growth promoters in chickens and swine, and are especially valuable in milk production in dairy cattle.
Abstract: The invention provides a nucleic acid having a sequence which encodes a polypeptide that is at least part of a T cell antigen receptor. This encoded sequence is about 936 nucleotides in length and preferably is a human T cell antigen receptor. The nucleic acid sequence of one embodiment of the invention is shown in FIG. 3.The nucleic acid sequence may be used as a probe to determine whether an unknown cell, e.g., a tumor cell, is a T cell.Polypeptides encoded by the nucleic acid sequence include about 312 amino acids and are at least part of a T cell antigen receptor. They include at least one sequence which over 21 contiguous amino acids has greater than about 35% homology with mouse and human immunoglobin .lambda. light chains.Antibody to the polypeptide may be prepared and used to identify T cell antigen receptor and to determine whether an unknown cell, e.g., a tumor cell, is a T cell.
Abstract: A bacterial insecticide containing an insecticidal substance produced by a practically reversionless asporogenous mutant of Bacillus thuringiensis, especially Bacillus thuringiensis serovar. kurstaki 290-1 and the process for the production in addition to a practically reversionless asporogenous mutant of Bacillus thuringiensis, especially Bacillus thuringiensis serovar. kurstaki 290-1 and the process for the production.
Abstract: This invention relates to the field of lignin degradation. More specifically the invention relates to methods for selecting and isolating microorganism from nature that are capable of degrading lignin, processes for cloning a gene segment from such an organism, and methods of using the enzyme product of the gene segment to provide valuable chemical feedstocks, methanol and the like from a lignin source material.
Type:
Grant
Filed:
September 27, 1984
Date of Patent:
December 15, 1987
Assignee:
Research Corporation Technologies, Inc.
Inventors:
Vadake R. Srinivasan, Jeffrey W. Cary, Younghae Chon, Kenneth E. Narva
Abstract: Disclosed is a method for the deletion of a gene from a bacteria using a single step procedure that is applicable to any essential or nonessential gene which has been cloned. The process requires the construction of chromosomal deletions by transformation of a cell strain with linear DNA fragments containing a locus for resistance to an antibiotic, or any other gene allowing for rapid phenotypic selection, flanked by sequences homologous to a closely spaced region on the cell chromosome. By selecting for a double-crossover event between the homologous sequences, shown by the antibiotic resistant or other detectable phenotype, a chromosome disruption can be selected for which has effectively deleted an entire gene.If the gene is essential to viability, the bacteria may be transformed with a plasmid which has a temperature-sensitive replicon and a wild-type allele of the essential gene. When E.
Abstract: Two types of convenient portable control cassettes for the expression of protein encoding sequences in procaryotes are disclosed. Both cassettes comprise the P.sub.L promoter from lambda phage, which is controllable by means of a temperature sensitive repressor, operably linked to the ribosome binding site for N-gene (N.sub.RBS). In one embodiment, this cassette is bordered by restriction sites upstream of the P.sub.L promoter and immediately downstream from the N.sub.RBS permitting the insertion of a desired sequence containing its own start codon downstream from the cassette. The other embodiment contains an ATG start codon within the cassette and has a restriction site immediately 3' of the start codon.
Abstract: The present invention relates to pseudorabies virus mutants containing deletion and/or insertion mutations in a major viral glycoprotein gene, such that no antigenic polypeptides encoded by the viral gene are produced. As a result, animals vaccinated with such do not develop antibodies to the viral glycoprotein and can be distinguished from animals infected with pseudorabies virus field strains and known pseudorabies virus vaccine strains. The present invention also relates to vaccines for pseudorabies disease containing the same, methods for production of the same and methods for use of the same.
Type:
Grant
Filed:
January 28, 1986
Date of Patent:
December 8, 1987
Assignees:
NovaGene, Inc., Baylor College of Medicine
Abstract: Secretin, which cannot be prepared directly by genetic engineering because of its carboxylic acid carboxyl-terminus, can be obtained by preparing secretylglycine by genetic engineering and then obtaining secretin therefrom by enzymatic conversion of the terminal glycine radical. The gene for the secretylglycine is synthesized chemically from smaller single-stranded units which are linked enzymatically to give the complete gene, incorporated into a suitable vector and amplified therein, after which the peptide is isolated directly or as a fusion protein and, after cyanogen bromide cleavage, is converted enzymatically into secretin.
Type:
Grant
Filed:
August 8, 1984
Date of Patent:
December 8, 1987
Assignee:
501 Hoechst Aktiengesellschaft
Inventors:
Wolfgang Konig, Joachim Engels, Eugen Uhlmann, Waldemar Wetekam
Abstract: The plasmids pDR401 and pDR412 are disclosed which contain a selectable chloramphenicol resistance gene and which are able to replicate in both T. ferrooxidans and E. coli. A process for constructing the plasmids is also described.
Type:
Grant
Filed:
November 1, 1984
Date of Patent:
December 8, 1987
Assignee:
General Mining Union Corporation, Limited
Abstract: The invention discloses a method for producing modified signal peptides sequences derived from wild-type signal peptide sequences of the type that are capable of forming membrane-bound lipoproteins. Modified signal peptide sequences produced by the method of the invention are useful for increasing the secretion of heterologous gene products produced by transformed host organisms. The invention further discloses a method for producing recombinant DNA sequences in vivo.